Compare Inovio Pharmaceuticals Inc (INO) vs MGM Resorts International (MGM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs MGM Resorts International — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while MGM Resorts International trades at $45.92 (market cap $11.86B). The key difference: MGM Resorts International is far larger — about 132.9× Inovio Pharmaceuticals Inc's market cap, and MGM Resorts International pays a 0.03% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | MGM | |
|---|---|---|
Market Cap | $89.27M | $11.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $2.87 | $50.69 |
52-Week Low | $1.05 | $30.72 |
Enterprise Value | $60.28M | $40.90B |
Dividend Yield | — | 0.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
MGM Resorts International (MGM) trades at $46.55, up 0.91% today, amid ongoing acquisition talks with Barry Diller's People Inc. at $48.30 per share. The stock shows mixed technical signals with a bullish moving average trend but neutral oscillators. Fundamentally, revenue grew to $17.54B in 2025, though net income margin compressed to 1.03%. Analyst consensus is evenly split between Buy and Hold, with a $48.93 price target suggesting modest upside from current levels.
MGM's outlook is clouded by acquisition uncertainty and declining profitability, offset by potential takeover premium and stable revenue. Key risks include execution on margin improvement, high debt levels, and macroeconomic sensitivity. The stock presents a speculative opportunity tied to deal completion, with fundamental challenges requiring careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →
